
    
      This is a dose-ranging multicenter, multinational, randomized, double-blind,
      placebo-controlled, parallel arm study with 4 SSR149744C dose regimens and amiodarone as a
      calibrator.To be eligible, patients must be in normal sinus rhythm for at least one hour at
      randomization and must have an electrocardiogram documented history of recent AF/AFL reverted
      to normal sinus rhythm by electrical, pharmacological or spontaneous conversion.
    
  